PD-1／PD-L1信号通路抗肿瘤抑制剂的研究进展

Progress on antitumor inhibitors of PD-1/PD-L1 signaling pathway

程序性细胞死亡受体1(programmed death 1,PD-1)及其配体(programmed death ligand 1,PD-L1)通路在许多实体瘤中过度激活,有助于肿瘤细胞免疫逃逸,所以阻断PD-1和PD-L1信号通路是恢复肿瘤特异性T细胞免疫能力从而治疗肿瘤的一个有效策略。目前,已有抗PD-1/PD-L1信号通路单克隆抗体药物上市,用于非小细胞肺癌、膀胱癌、三阴性乳腺癌及黑色素瘤等实体瘤的治疗。除了抗体药物外,靶向PD-1/PD-L1信号通路的肽类以及小分子抗癌药物也已成为研究热点。本文对近年来PD-1/PD-L1信号通路抑制剂在肿瘤治疗中的研究现状及进展进行总结。

Program cell death receptor 1 （PD-1） and its ligand（ PD-L1 ） pathway in many solid tumors are activated and contributed to tumor cell immune escape. At present, monoclonal antibody drugs against PD-1/ PD-L1 signaling pathway have been used in the treatment of solid tumors, and the curative effect is remarkable. In addition to antibody drugs,peptide antagonist and small molecule drugs have also become a hot topic in blocking the PD-1/PD-L1 signaling pathway for the treatment of solid tumors. This paper aims to review and summarize recent research status and progress of immunotherapy of PD-1/PD-L1 signaling pathway inhibitors in cancer therapy.